Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Cancer Res. 2019 May 2;79(13):3466–3478. doi: 10.1158/0008-5472.CAN-18-3014

Figure 3. MHCII Immune Activation assay in an independent validation cohort of FFPE TNBC tumors.

Figure 3.

(A) Expression of MHCII and TIL genes are highly correlated within TNBC patient tumors in the independent validation cohort. (B) Immune Activation Scores calculated using MHCII and TIL genes in the MHCII Immune Activation assay were significantly higher in patients who did not relapse. Mean and 95% confidence interval shown. Threshold is a dashed line, red circle classified as high, blue circle classified as low. (C) A Kaplan Meier curve and log rank p-value show significantly longer DFS in patients with high Immune Activation Scores using the threshold depicted in 3B.